THERAPY DOSSIER · th-9d6449d0e430

Yttrium oxide (Y2O3) nanoparticles, approximately 10 to 14 nm diameter

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25066531 ↗2014Reported benefit

Yttrium oxide nanoparticles prevent photoreceptor death in a light-damage model of retinal degeneration.

MouseRadiationBALB/c (albino)n = n = 8 to 12 eyes per group for electroretinography; at leas…Intravitreal (trans-scleral) injection2 microlitres of 0.1, 1.0 or 5.0 micromolar nanoparticle su…Pre-treatment 13 to 15 days before light exposure, or immediately (2 h) after l…

Model: Light damage model: 48 h dark adaptation followed by 2 h exposure to 8,000 lux constant bright light

Pre-treatment at 0.1 to 5.0 micromolar preserved scotopic and photopic ERG amplitudes and outer nuclear layer structure, with complete functional protection at 5.0 micromolar. Post-treatment was effective only at 1.0 micromolar and gave a smaller benefit. Nanoparticles alone caused no retinal toxic…

Extraction: extract · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.

Loading the evidence…